StageAngel - II | Alive
Last Raised$1.75M | 11 yrs ago
Psoria-Shield advocates the use of targeted UV phototherapy to address those aspects of patients' disease which reduce Quality of Life. By addressing the major detractors from patients' Quality of Life initially, patients and healthcare providers can address the remaining regions of skin with less aggressive therapy.
Missing: Psoria-Shield's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Psoria-Shield's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Psoria-Shield
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Psoria-Shield is included in 1 Expert Collection, including Medical Devices.
Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)
Latest Psoria-Shield News
Nov 27, 2018
| Source: Wellness Center USA, Inc. HOFFMAN ESTATES, IL, Nov. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Wellness Center USA, Inc. (OTCQB: WCUI) and Psoria-Shield, Inc. (PSI) today announced the formation of a Joint Venture between Psoria-Shield, Inc and PSI Gen 2 Funding, Inc. (“GEN2”), to further development of their next generation phototherapy device. The Joint Venture will be conducted through Neo Phototherapy, LLC (“NEO”), a recently formed Illinois limited liability company. The next generation Class II medical device is the result of 24 months of product R&D and market research based on the previous Psoria-Light (“PL 1000”) and will utilize a new custom LED emitter array, operate on a new native software platform, use current SOTA high efficient microprocessor systems, and will be smaller, lighter, quieter, and more efficient than the current PL 1000 device. The unique LED technology in development will allow NEO to provide clinicians with a compact, easy to use, light weight and portable UVA-UVB emitting device (approx. 8.5 lbs.). Phototherapy treatment is expected to expand significantly beyond the current 16,000 dermatologists to the more than 327,000 general practice and internal medicine physicians, who previously did not treat patients, but referred them to specialists. Besides treating psoriasis, eczema, and vitiligo, the next generation device is designed to be expandable to include added LED wavelengths for additional treatment applications for other medical and cosmetic conditions. Per the Joint Venture arrangement, which was announced in an 8K filing on November 21, 2018, PSI and GEN2 will be members of NEO, owning 58.5% and 28.0%, respectively, of NEO’s interests (“Units”), with an additional 13.5% of such Units reserved for issuance as incentives for key employees and consultants retained from time to time by NEO in connection with the Venture. PSI will contribute PSI Technology to NEO and GEN2 will contribute $700,000.00, through the period ending January 31, 2019. GEN2 consists of accredited investors, and investment participation from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch. The next generation prototype units are anticipated by the end of Q1 2018. About Wellness Center USA, Inc. Wellness Center USA, Inc. ( www.wellnesscenterusa.com ) is a hybrid healthcare company that combines best in class technologies, software, devices, providers, protocols, goods, and services. It was created to address important healthcare and wellness needs via breakthrough solutions, all centered around the “well‐being of the body and mind”. Wellness Center USA, Inc. is the parent company of two businesses reporting consolidated: Stealth Mark and Psoria‐Shield . Safe Harbor Statement: Certain statements and projections contained in this presentation that are not statements or financial results of historical fact constitute forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements and projections include statements regarding any proposed exchange transactions, the anticipated closing date of such transactions and future results following a closing of the transactions. Forward‐looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words like “believe,” “expect,” “anticipate,” “pending”, “estimate,” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.” While it is not possible to identify all factors, risks and uncertainties that might relate to, affect or arise from the proposed transactions and plans which might cause actual results to differ materially from expected results, such factors, risks and uncertainties include delays in completing the transactions, difficulties in integrating operations following the transactions, difficulties in manufacturing and delivering products, potential market rejection of products or services, increased competitive pressures, changes in general economic conditions, legislative and regulatory changes that adversely affect the business in which the parties are engaged, changes in the securities markets and other factors, risks and uncertainties disclosed from time to time in documents that the Company files with the SEC. Contact Info:At Wellness Center USA, Inc. Tel: (847) 925‐1885 www.wellnesscenterusa.comJ. Charles AssetsInvestor RelationsTel: (407) 627-0167www.jcharlesassets.com Related Articles
Psoria-Shield Frequently Asked Questions (FAQ)
Where is Psoria-Shield's headquarters?
Psoria-Shield's headquarters is located at 6408 West Linebaugh Avenue, Tampa.
What is Psoria-Shield's latest funding round?
Psoria-Shield's latest funding round is Angel - II.
How much did Psoria-Shield raise?
Psoria-Shield raised a total of $2.63M.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.